戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  placebo, including depression, anxiety, and akathisia.
2 essness, along with nonmotor wearing off and akathisia.
3 ory, response inhibition, mood, anxiety, and akathisia.
4 loperidol decanoate was associated with more akathisia.
5 stonia, tremor, myoclonus, stereotypies, and akathisia.
6        Molindone led to more self-reports of akathisia.
7 ues and assessment of movement disorders and akathisia.
8 cantly larger increases in global ratings of akathisia (0.73 [95% CI, 0.59-0.87] vs 0.45 [95% CI, 0.3
9 emergent adverse event for brexpiprazole was akathisia (2 mg: 4.4%; 4 mg: 7.2%; placebo: 2.2%).
10 ; they also had significantly les observable akathisia (24% versus 53%) and significantly less severe
11 gent adverse events were somnolence (10.0%), akathisia (7.7%), and sedation (7.7%) in the open-label
12 epressive symptoms, baseline motor function, akathisia and dystonia during treatment, growth hormone
13 gnificantly greater reductions in tremor and akathisia and greater improvements in most items on the
14 uality of life, and its benefits in reducing akathisia and improving cognition must be balanced with
15 >/=10%) in cariprazine-treated patients were akathisia and insomnia; weight gain was slightly higher
16 azine group and twice the placebo rate) were akathisia and nausea.
17 erability concerns include the potential for akathisia and Parkinsonism.
18 se events and aripiprazole with more initial akathisia and, unexpectedly, more sedation.
19 ts with respect to measures of parkinsonism, akathisia, and dyskinesias.
20  dry mouth, increased appetite, weight gain, akathisia, and high alanine aminotransferase levels; tho
21  lurasidone were nausea, somnolence, tremor, akathisia, and insomnia.
22 tatic model of insulin resistance (HOMA-IR), akathisia, and sedation.
23 iated with lurasidone were nausea, headache, akathisia, and somnolence.
24 sitive symptoms, conceptual disorganization, akathisia, and tardive dyskinesia.
25 ide effects; 6) extrapyramidal side effects, akathisia, and tardive dyskinesia; 7) cataracts; and 8)
26 ment-aripiprazole group included somnolence, akathisia, and weight gain.
27  linked to several adverse events, including akathisia (aripiprazole), sedation (quetiapine, OFC, and
28  rate of treatment-emergent parkinsonism and akathisia but had significantly more weight gain, compar
29 idol group reported symptoms consistent with akathisia, compared with six (20%) patients in the zipra
30 om outcomes and measures of parkinsonism and akathisia did not differ between medications.
31  the rate of the placebo group) were nausea, akathisia, dizziness, and sedation.
32 cularly with olanzapine), fatigue, sedation, akathisia (for aripiprazole), and extrapyramidal symptom
33 ette's syndrome, restless legs syndrome, and akathisia, have traditionally been considered to be diso
34       Olanzapine was associated with reduced akathisia in the intention-to-treat analysis (P<.001) an
35 hostility and the Simpson-Angus Rating Scale akathisia item.
36 ms (KarXT, zero [0%] vs placebo, zero [0%]), akathisia (one [1%] vs one [1%]), weight gain (zero [0%]
37       There were no adverse event reports of akathisia or other extrapyramidal motor side effects; me
38 Es) and scales used to monitor parkinsonism, akathisia/restlessness, anxiety, depression, suicidality
39 ements in the Simpson-Angus scale and Barnes Akathisia Scale scores, while haloperidol-treated patien
40 amidal symptoms (Simpson-Angus Scale, Barnes Akathisia Scale, Abnormal Involuntary Movement Scale) we
41 Abnormal Involuntary Movements Scale, Barnes Akathisia Scale, and Modified Simpson-Angus [for Extrapy
42 ormal Involuntary Movement Scale, the Barnes Akathisia Scale, the Simpson-Angus Scale, and the Arizon
43 using the Simpson-Angus Scale and the Barnes Akathisia Scale; abnormal involuntary movements were ass
44 , weight gain, antiparkinson medication use, akathisia, serum prolactin level, QTc prolongation, and
45 rkinsonian symptoms and quetiapine with less akathisia than haloperidol, aripiprazole, risperidone, a
46                  In addition to sedation and akathisia, the most common adverse events were tremor (4
47                             The incidence of akathisia was higher with 120 mg of lurasidone (22.9%) t
48                                              Akathisia was more common with aripiprazole at week 2 (o
49                                              Akathisia was the most common adverse effect of aripipra
50 gain, no extrapyramidal disorder except rare akathisia were observed under F17464.
51                  Extrapyramidal symptoms and akathisia were similar in the two groups, although no an
52 tment-emergent adverse events (eg, insomnia, akathisia, worsening of schizophrenia, headache, anxiety